Related Experiment Video
Updated: Jun 18, 2026
Ambulatory ECG Recording in Mice
Published on: May 27, 2010
Macrophage-dependent IL-1β production induces cardiac arrhythmias in diabetic mice
Gustavo Monnerat1, Micaela L Alarcón1, Luiz R Vasconcellos2,3
1Institute of Biophysics Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Abstract:
Diabetes mellitus (DM) encompasses a multitude of secondary disorders, including heart disease. One of the most frequent and potentially life threatening disorders of DM-induced heart disease is ventricular tachycardia (VT). Here we show that toll-like receptor 2 (TLR2) and NLRP3 inflammasome activation in cardiac macrophages mediate the production of IL-1β in DM mice. IL-1β causes prolongation of the action potential duration, induces a decrease in potassium current and an increase in calcium sparks in cardiomyocytes, which are changes that underlie arrhythmia propensity. IL-1β-induced spontaneous contractile events are associated with CaMKII oxidation and phosphorylation. We further show that DM-induced arrhythmias can be successfully treated by inhibiting the IL-1β axis with either IL-1 receptor antagonist or by inhibiting the NLRP3 inflammasome. Our results establish IL-1β as an inflammatory connection between metabolic dysfunction and arrhythmias in DM.
Insights
Diabetes mellitus causes heart arrhythmias via IL-1β, driven by toll-like receptor 2 (TLR2) and NLRP3 inflammasome activation. Inhibiting IL-1β effectively treats these dangerous heart rhythm disorders.
Area of Science:
- Cardiology
- Immunology
- Metabolic disorders
Background:
- Diabetes mellitus (DM) is linked to secondary heart conditions, including life-threatening ventricular tachycardia (VT).
- Inflammatory pathways are increasingly recognized as contributors to diabetic heart disease complications.
Purpose of the Study:
- To investigate the role of toll-like receptor 2 (TLR2) and NLRP3 inflammasome in mediating cardiac inflammation and arrhythmias in diabetes.
- To explore the therapeutic potential of targeting the IL-1β pathway for treating diabetic heart arrhythmias.
Main Methods:
- Utilized a mouse model of diabetes mellitus.
- Assessed activation of TLR2 and NLRP3 inflammasome in cardiac macrophages.
- Measured IL-1β production and its effects on cardiomyocyte electrophysiology and calcium handling.
- Evaluated the efficacy of IL-1 receptor antagonist and NLRP3 inflammasome inhibition in treating DM-induced arrhythmias.
Main Results:
- DM mice exhibited activation of TLR2 and NLRP3 inflammasome in cardiac macrophages, leading to increased IL-1β production.
- IL-1β was found to prolong action potential duration, decrease potassium current, and increase calcium sparks in cardiomyocytes, promoting arrhythmia.
- IL-1β-induced spontaneous contractile events were linked to CaMKII oxidation and phosphorylation.
- Inhibition of the IL-1β axis, via IL-1 receptor antagonist or NLRP3 inflammasome inhibition, successfully treated DM-induced arrhythmias.
Conclusions:
- IL-1β acts as a critical inflammatory mediator connecting metabolic dysfunction in diabetes to cardiac arrhythmias.
- Targeting the IL-1β inflammatory pathway represents a promising therapeutic strategy for managing heart rhythm disorders in diabetic patients.
